-
HA230 Applied in a Patient Suffering from Severe D...2023-09-06 -
Jafron Q3 Report 2022: Prepping for the Winter2023-09-06 -
Jafron：Master the acute phase2023-09-06 -
The first Vietnam clinical case competition was su...2023-09-06 -
Jafron HA130 in Medical Research: Another Breakthr...2023-09-06 -
The way forward of Jafron in Europe2023-09-06 -
A Clinical Case about Septic Shock from Vietnam2023-09-06 -
Jafron Biomedical at the 40th Vicenza Course on AK...2023-09-06 -
Jafron Presents at the 59th ERA Congress2023-09-06
-
HA230 Applied in a Patient Suffering from Severe Deltamethrin Poisoning2023-09-06
-
Jafron Q3 Report 2022: Prepping for the Winter2023-09-06
-
Jafron：Master the acute phase2023-09-06
-
The first Vietnam clinical case competition was successfully held2023-09-06
-
Jafron HA130 in Medical Research: Another Breakthrough2023-09-06
-
The way forward of Jafron in Europe2023-09-06
-
A Clinical Case about Septic Shock from Vietnam2023-09-06
-
Jafron Biomedical at the 40th Vicenza Course on AKI&CRRT2023-09-06
-
Jafron Presents at the 59th ERA Congress2023-09-06
Jafron Biomedical Co., Ltd.
Address : No. 98 Technology Six Road, High-tech Zone, Zhuhai City, China
E-mail : customerservice@jafron.com
Website : https://www.jafroninternational.com
Terms of Use｜Site Map｜ Cookie Notice｜ Privacy Notice
Recruitment Privacy Notice｜ 7/24 Hotline
© 2016 Jafron Biomedical Co., Ltd. All rights reserved.
Recruitment Privacy Notice｜ 7/24 Hotline
© 2016 Jafron Biomedical Co., Ltd. All rights reserved.
